Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…
Allogene Therapeutics, Inc.
Next earnings ≈ Aug 12, 2026 · est. from filing cadence
Last earnings +1.3% on 2026-05-13
Conservative balance sheet (liabilities/equity 0.42x); but revenue fell -100.0% YoY.
Rules-based read computed from SEC figures — no Anthropic key set. Add ANTHROPIC_API_KEY to .env.local for a full Claude analysis.
Allogene Therapeutics, Inc. shows $0.00 in FY2025 revenue (-100.0% YoY), and -65.3% ROE.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
Sources: SEC EDGAR (CIK 0001737287, latest 10-Q filed 2026-05-13) · EODHD · rules-based read · as of 6/18/2026, 2:00:52 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $114M | $156K | $95.0K | $22.0K | $0.00 |
| Gross profit | — | — | — | — | — |
| Operating income | -$180M | -$336M | -$328M | -$273M | -$209M |
| Net income | -$182M | -$340M | -$327M | -$258M | -$191M |
| Diluted EPS | -$1.34 | -$2.38 | -$2.09 | -$1.32 | -$0.87 |
| Net margin | -159.6% | -218214.1% | -344489.5% | -1170863.6% | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
501 tracked peers · median
Last 90 days: 0 open-market buys · 2 sales
| 2026-04-21 | Yoshiyama Annie SVP, Finance | Sell | 9.59K @ $2.31 | $22.1K |
| 2026-03-31 | Beneski Benjamin Machinas SVP, Chief Technical Officer | Sell | 2.87K @ $2.50 | $7.17K |
| 2026-03-16 | Beneski Benjamin Machinas SVP, Chief Technical Officer | Sell | 4.83K @ $2.47 | $11.9K |
| 2026-03-16 | Chang David D President and CEO | Sell | 47.8K @ $2.47 | $118K |
| 2026-03-02 | Beneski Benjamin Machinas SVP, Chief Technical Officer | Sell | 7.13K @ $2.60 | $18.5K |
| 2026-02-02 | Beneski Benjamin Machinas SVP, Chief Technical Officer | Sell | 7.55K @ $1.73 | $13.1K |
| 2026-02-02 | Chang David D President and CEO | Sell | 95.3K @ $1.80 | $171K |
| 2026-02-02 | Parker Geoffrey M. CHIEF FINANCIAL OFFICER | Sell | 24.0K @ $1.76 | $42.2K |